This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
169
Setipiprant tablets, orally, BID for 24 weeks.
Placebo tablets, orally, BID for 24 weeks.
Finasteride tablet, orally, once daily for 24 weeks.
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Petrus Center for Aesthetic Surgery & Hair Transplantation
Change From Baseline in Target Area Hair Count (TAHC) at Week 24
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
Time frame: Baseline (Day 1) to Week 24
Subject Self-Assessment (SSA) Score in Hair Growth at Week 24
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
Time frame: Week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Little Rock, Arkansas, United States
Therapeutics Clinical Research
San Diego, California, United States
Radiant Research, Inc.
Santa Rosa, California, United States
DeNova Research
Chicago, Illinois, United States
Heartland Research Associates, LLC
Wichita, Kansas, United States
Michigan Center for Skin Care Research
Clinton Township, Michigan, United States
Minnesota Clinical Study Center
Fridley, Minnesota, United States
University of Minnesota Department of Dermatology Division of Clinical research
Minneapolis, Minnesota, United States
Wake Forest University Health Sciences Department of Dermatology Medical Center Boulevard
Winston-Salem, North Carolina, United States
...and 8 more locations